Repligen Co. (NASDAQ:RGEN) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 425,412 shares of the biotechnology company's stock after selling 17,676 shares during the quarter. New York State Common Retirement Fund owned 0.76% of Repligen worth $76,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Artisan Partners Limited Partnership boosted its position in Repligen by 11.3% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company's stock valued at $247,558,000 after buying an additional 157,807 shares during the period. Wellington Management Group LLP raised its position in shares of Repligen by 2.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company's stock worth $222,075,000 after purchasing an additional 29,215 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Repligen by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company's stock worth $190,117,000 after purchasing an additional 137,220 shares in the last quarter. Conestoga Capital Advisors LLC grew its position in Repligen by 0.4% during the 4th quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company's stock valued at $127,611,000 after purchasing an additional 2,590 shares during the last quarter. Finally, Parnassus Investments LLC purchased a new position in Repligen in the 3rd quarter worth approximately $87,475,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Buying and Selling at Repligen

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company's stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Anthony Hunt sold 16,707 shares of the firm's stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock worth $5,039,532 in the last quarter. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

NASDAQ:RGEN traded down $3.42 during trading hours on Wednesday, hitting $167.86. 545,955 shares of the stock traded hands, compared to its average volume of 538,751. The company has a market cap of $9.37 billion, a price-to-earnings ratio of 231.10, a price-to-earnings-growth ratio of 5.16 and a beta of 1.02. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The stock has a 50 day moving average price of $186.62 and a 200 day moving average price of $173.56. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm's quarterly revenue was down 16.6% on a year-over-year basis. During the same quarter last year, the company earned $0.68 EPS. Sell-side analysts forecast that Repligen Co. will post 1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the subject of several research analyst reports. Stifel Nicolaus lifted their price objective on Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. KeyCorp boosted their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.